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Summary
Objective: Chondroitin sulfate (CS) has proven to be a valuable therapeutic tool as a symptomatic slow-acting drug for the treatment of
osteoarthritis after oral administration. The aim of this study was to assess the absorption of CS of ichthyic origin after oral administration to
20 healthy male volunteers.
Design: Ichthyic origin CS (from shark cartilage, 4 g) was orally administered to 20 healthy human volunteers, and then extracted and purified
from plasma over a 48 h period. The polysaccharide absorbed by oral route was characterized and quantified by agarose-gel electrophoretic
technique, and densitometric scanning. In addition, the percentage of constituent disaccharides and charge density were measured.
Results: After oral administration, ichthyic CS plasma levels increased (more than 120%) with a peak concentration at 8.7 h, with the
increase reaching significance from 4 to 16 h. A significant decrease in the relative amount of non-sulfated disaccharide was measured
(reaching the minimum relative percentage of 30.86±20.79% at 8 h). At the same time, 4-sulfated disaccharide increased to a maximum of
51.91±25.91% at 6 h, and 6-sulfated and disulfated disaccharides appeared in blood, reaching maximum concentrations of 15.24±16.60%
at 8 h and 2.93±4.82% at 12 h, respectively. Concomitantly, the mean charge density rose from 0.40±0.14 at predose to a maximum of
0.72±0.22 and 0.72±0.21 measured 8 and 12 h after ichthyic CS administration.
Conclusions: Ichthyic CS is absorbed slowly, with a tmax8.74.5 h and the Cmax averaged 4.87±2.05 µg/ml. The differences in the
absorption and bioavailability of the various CS formulations is strongly influenced by the structure and characteristics, such as molecular
mass, charge density, and cluster of disulfated disaccharides, of the parental molecules.
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2-acetamido-2-deoxy-3-0-(4-deoxy-α-L-threo-hex-4-enepyranosyluronic acid)-D-galactose 6-sulfate, ∆Di-2,6dis,
2-acetamido-2-deoxy-3-0-(4-deoxy-2-O-sulfo-α-L-threo-hex-4-enepyranosyluronic acid)-6-O-sulfo-D-galactose, ∆Di-4,6dis,




Osteoarthritis is a heterogeneous condition with various
clinical expressions1. The most common symptoms are
pain and functional disability resulting from destructive
changes of the osteoarthritic joint. Current treatment of
osteoarthritis is not aimed at a cure but at palliative man-
agement including physical, pharmacological, and surgical
approaches. Drug treatment includes analgesics, NSAIDs,
and symptomatic slow-acting drugs (SYSADOA)2–5. The
latter class of compounds have a slow onset of action and
improve osteoarthritis symptoms6. Some of them are
administered orally and some intra-articularly. Among
SYSADOA, chondroitin sulfate (CS) has proven to be a
valuable therapeutic tool for the symptomatic treatment of
osteoarthritis. Several controlled trials showed its effects as
a SYSADOA with application in the therapy of osteoarthritis
of the knee and in articular cartilage osteoarthritis6–11 with
very good tolerability12,13. Furthermore, whether CS will be
shown to have a disease-modifying effect will be seen14.
CSs are heteropolysaccharides purified from various
tissues composed of alternate sequences of uronic acids
(D-glucuronic or L-iduronic) and differently sulfated residues
of N-acetyl-D-galactosamine linked by β(1->3) bonds15–17.
The regular disaccharide sequence of chondrotin sulfate
A, chondroitin-4-sulfate, is constituted by [(1->4)-O-
(D-glucopyranosyluronic acid)-(1->3)-O-(2-N-acetamido-2-
deoxy-D-galactopyranosyl-4-sulfate)]. Chondrotin sulfate C,
chondroitin-6-sulfate, is mainly composed of a disaccharide
unit [(1->4)-O-(D-glucopyranosyluronic acid)-(1->3)-O-(2-N-
acetamido-2-deoxy-D-galactopyranosyl-6-sulfate)]. Disac-
charides with a different number and position of sulfate
groups can be located, in different percentages, inside
the polysaccharide chains, such as the non-sulfated or
disulfated disaccharide in which two sulfate groups
are O-linked in position 2 of D-glucuronic acid and 6 of
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N-acetyl-D-galactosamine (disaccharide D) or in position 4
and 6 of N-acetyl-D-galactosamine (disaccharide E). These
heterogeneous structures, in terms of percentage of vari-
ously sulfated disaccharides, degree of sulfation, molecular
mass, relative amounts of iduronic acid, and glucuronate
depending on the tissue of origin, are responsible for
different and more specialized functions of these
glycosaminoglycans18–24.
CS is mainly employed by the oral route allowing a more
simple drug use compatible with long term adminis-
tration6,10,11,25. In a previous study26, bovine CS was orally
administered to 20 healthy human volunteers and extracted
and purified from plasma over a 48 h period. After oral
administration, CS plasma levels increased (more than
200%). Absorption of exogenous CS was also proved by
the change in the composition of disaccharides in plasma
after drug administration with respect to baseline.
As CS extracted from shark is one of the SYSADOA used
in Europe for the treatment of osteoarthritis14, a study was
performed to assess the absorption of ichthyic origin CS
after oral administration to 20 healthy male volunteers, and
to compare bioavailability of CS obtained from two different
sources, ichthyic and bovine26. This last point could be of
interest to better design a more effective therapy related to
the very different structural and functional properties of the
two polysaccharides. In the present study, ichthyic origin
CS was orally administered to 20 healthy human volun-
teers, and extracted and purified from plasma over a 48 h
period. Polysaccharide absorbed by the oral route was
characterized using the previously reported analytical ap-
proach26. Pharmacokinetic parameters were determined
and the percentage of constituent disaccharides and
charge density were measured.
Experimental methods
SUBJECTS
The 20 healthy male volunteers participating in the study
were the same volunteers reported for the previous phar-
macokinetic study26. The Clinical Investigator gave his
approval for the participation of each subject in the study,
on the basis of acceptable medical history and findings in
the physical and instrumental (ECG, laboratory) examin-
ations. Written informed consent was obtained prior to their
inclusion in each study period, as per protocol.
See previous study26 for the healthy volunteers details.
The volunteers had the ability to comprehend the full nature
and purpose of the study, to cooperate with the investigator,
and to comply with the requirements of the study. They
gave written informed consent.
STUDY PROTOCOL
This was an open, single centre, single dose study. Ten
capsules of ichthyic origin CS 400 mg, expiry date 1/2002,
were administered as a single oral dose. The active drug
was constituted of ichthyic origin CS (from shark cartilage),
as also confirmed by disaccharide pattern evaluation (see
subsequently).
The study drugs were provided by Institut Biochimique
S. A. (IBSA, CH-6915 Pambio Noranco, Lugano, Svizzera)
to the Clinical Centre (Cross Research S. A. Phase I Unit,
CH-6864 Arzo, Svizzera) in excess of the amount neces-
sary for the study (25% excess). The study medications
were stored in a cool, safe locked place and were dis-
pensed only by the investigator or authorised personnel.
The study drug was exclusively used for the present clinical
trial and was only administered to the subjects enrolled in
the study. At the end of the study, all the unused supplies
were returned to the sponsor, after assessment of drug
accountability.
Subjects took no food or drink (apart from water) for
approximately 12 h (i.e., overnight) before administration,
and for up to 2 h after treatment. Starting from 24 h before
drug administration, the intake of food containing high
quantities of glycosaminoglycans was kept low. The previ-
ous day’s dinner before each drug administration was
consumed at the clinical centre. A standardised light break-
fast was served at approximately 10 a.m. (2 h after drug
administration), lunch at approximately 1 p.m. (after the fifth
hour of sampling), and dinner at approximately 8 p.m. (after
the 12th hour of sampling).
The volunteers were asked to avoid physical activity
during the 3 days preceding the starting of study. The
evening preceding drug administration and the start of
blood sampling, volunteers were hospitalised in the Clinical
Centre.
The study periods included a single oral administration at
about 8 a.m. of day 1, followed by a 48 h observation
period. On the last day of the study period (day 3), each
volunteer underwent blood and urine tests and electrocar-
diogram evaluation for post-study assessment. During the
study period, a single administration was performed on day
1 at 8–8:33 a.m. Each volunteer swallowed 10 capsules of
the test drug (400 mg) together with 400 ml of tap water
(200 ml just before and 200 ml during administration).
High doses of CS (4 g) with respect to the standard
therapeutic doses14 were administered to the healthy
volunteers to permit a better quantitative and qualitative
evaluation of the polysaccharide absorbed.
PLASMA SAMPLES COLLECTION
Venous blood samples (15 ml) were taken from a vein of
the forearm using an indwelling catheter. The cannula was
rinsed after each sampling. Blood samples were collected
in tubes containing citrate as anticoagulant at the following
times: predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, and 48 h
after drug intake. The samples were immediately stored at
4°C, centrifuged within 1 h at 4°C for 10 min to obtain
plasma and immediately divided into two 2.5 ml aliquots,




Protease type XXI from Streptomyces griseus [E.C.
3.4.24.31] was from Sigma. Ecteola-cellulose (conden-
sation product of epichlorohydrin, triethanolamine, and
cellulose, cross-linked fibres; capacity of 0.3–0.4 mEq/g,
particle size of 0.05–0.2 mm) was from Serva, Heidelberg,
Germany. High purity agarose and barium acetate were
from BioRad. 1,2-Diaminopropane and cetyltrimethylam-
monium bromide were from Merck, Darmstadt, Germany.
Spherisorb SAX (5 µm) (trimethylammoniopropyl groups
Si–CH2–CH2–CH2–N+ (CH3)3 in Cl− form) was from Phase
Separations Limited, Deeside Industrial Park, Deeside
Clwyd, UK. Chondroitinase ABC from Proteus vulgaris
[E.C. 4.2.2.4] was obtained from Sigma. Non-sulfated and
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variously sulfated unsaturated CS disaccharides (∆Di-0s,
∆Di-4s, ∆Di-6s, ∆Di-2,6dis, ∆Di-4,6dis, ∆Di-2,4dis, ∆Di-
2,4,6tris, see abbreviations) were obtained from Seikagaku
Corporation, Tokyo, Japan. All the other reagents were of
analytical grade.
Extraction and purification of plasma CS
Extraction of CS from plasma samples was performed
according to the method reported elsewhere26. Five hun-
dred microlitres of protease from S. griseus (10 mg/ml
50 mM Tris–Cl buffer pH 8.0) was added to 1000 µl of
plasma. After incubation at 37°C for 24 h, 1000 µl 0.1 M
acetic acid and 500 µl NaCl 3 M were added. The mixtures
were boiled for 5 min, and then centrifuged at 5000g for
5 min, and 1000 µl NaOH 0.1 M was added to the super-
natants; 5 ml of acetone was then added and solutions
stored at −20°C for 24 h. The precipitates were recovered
by centrifugation at 5000g for 15 min and dried at 50°C for
12 h. The dried precipitates were dissolved in 1000 µl of
distilled water by prolonged mixing and, after centrifugation
at 10 000g for 5 min, the supernatant was applied to a
column (1 cm×2 cm) packed with approximately 1.5 ml of
Ecteola-cellulosa, previously washed with 1 M NaOH and
1 M HCl and equilibrated with 0.05 M NaCl. After washing
the resin with 10 ml of 0.05 M NaCl, 5 ml of 3 M NaCl was
added. Ten millilitres of acetone was added to the eluate
(5 ml) and stored at +4°C for 24 h. After centrifugation at
5000g for 15 min, the pellet was dried at 60°C for 6 h.
Agarose-gel electrophoresis
Validated agarose-gel electrophoresis was performed
according to Volpi26–28. Samples were dissolved in 20 µl
distilled water and layered on 0.5% agarose-gel plate and
run in 0.05 M 1,2-diaminopropane buffered to pH 9.0 with
acetic acid for 3 h at 60 mA. After migration, the plate was
soaked in cetyltrimethylammonium bromide (0.1% solution)
for approximately 12 h, dried and then stained with toluid-
ine blue (0.2% in ethanol–water–acetic acid, 50:49:1 v:v:v)
for 30 min and destained with ethanol–water–acetic acid
50:49:1 v:v:v.
Densitometric analysis was performed with a densito-
metric unit composed of Macintosh IIsi computer interfaced
to a Microtek Color Scanner from Microtek International
Inc., Hsinchu, Taiwan. The IMAGE processing and analysis
program, Version 1.41 from Jet Propulsion Lab., NASA,
Florida, USA was used for densitometric analysis of
agarose-gel bands.
Disaccharide composition of ichthyic CS after oral
administration
Samples dissolved in 40 µl (2–4 µg of purified CS) of
50 mM pH 8.0 Tris–HCl buffer were incubated with 50 mU
of chondroitinase ABC. The reactions were stopped after
3 h of incubation at 37°C, by boiling for 1 min. The constitu-
ent disaccharides were determined by SAX-HPLC at
232 nm26. Isocratic separation was run from 0 to 5 min with
0.1 M NaCl, pH 4.00; linear gradient separation from 5 to
30 min with 100% 0.1 M NaCl, pH 4.00 to 50% 1.2 M NaCl,
pH 4.00. Flow rate was 1.4 ml/min. Separation of un-
saturated non-sulfated and variously sulfated disac-
charides produced by the action of the bacterial lyase was
performed using standards supplied by Seikagaku Kogyo
Co.
The following parameters were provided after each
oral administration of CS: relative percentage of each
unsaturated disaccharide calculated per 500 µl of plasma,
namely ∆Di-0s (non-sulfated disaccharide), ∆Di-6s (6-
monosulfated disaccharide), ∆Di-4s (4-monosulfated disac-
charide), and ∆Di-dis (disulfated disaccharides). Therefore,
charge density (sulfate to disaccharide ratio) of ichthyic CS
was calculated.
Molecular mass determination of ichthyic CS
Molecular mass of ichthyic CS was determined by high-
performance size-exclusion chromatography (HPSEC).
HPLC was from Jasco. The mobile phase was composed
of 125 mM Na2SO4 and 2 mM NaH2PO4 adjusted to pH 6.0
with 0.1 N NaOH. Flow rate was 0.9 ml/min. Columns were
Protein Pak 125 (Waters, 7.8 mm×30 cm) and Protein
Pak 300 (Waters, 7.5 mm×30 cm) assembled in series.
The retention times were plotted against the logarithm of
molecular mass for standard glycosaminoglycans29,30. The
curve that fits the experimental data is a third grade
polynomial with the formula y(fx)ax3bx2−cx+d re-
ported in the Figure. The number of average molecular
weight (Mn, expressing the amount of species by the
number of moles), the weight average molecular weight
(Mw, considering the mass of the species), and the poly-
dispersity index (Mw/Mn) were calculated by the Jasco
Borwin GPC software version 4.1 (from Jasco, Japan).
PHARMACOKINETIC PARAMETERS31–33
The percentage increase in CS with respect to baseline
value was calculated at each time point after drug ad-
ministration. The following pharmacokinetic parameters
were obtained from the individual values of CS plasma
concentrations (µg/ml) vs time (hours), determined up
to 48 h after ichthyic CS administration, using the vali-
dated software KINETICA™ 2000 version 3.0, InnaPhase
Corporation, Philadelphia, USA (KINETICA 2000 User’s
Manual, Innaphase Corporation, Philadelphia, USA,
1999):
Cmax: The highest concentration value found in plasma.
tmax: The time from administration at which
the Cmax value is found.
AUC0–48: The area under the plasma concentration vs
time curve up to the last sampling time calculated by
the linear–linear trapezoidal rule.
AUC0–24: The area under the plasma concentration vs
time curve up to the 24 h sampling time calculated by
the linear–linear trapezoidal rule.
STATISTICAL ANALYSIS
The data documented in this trial and the parameters
measured were compared and evaluated using classic
statistics: mean, standard deviation, coefficient of variation
(%), minimum and maximum values (for quantitative
variables), and by frequencies (qualitative variables).
Descriptive statistics were performed by means of either
SAS® version 8e for Windows® (SAS/STAT® User’s Guide,
Version 6, Fourth Edition, SAS Institute Inc., Cary, NC,
USA, 1990) or Kinetica™.
The CS plasma concentrations, µg/ml plasma CS for
each time, measured after drug treatment, were compared
to basal values (see previous study26) by means of a t-test.
The ANOVA test was then applied to compare within the
group the increase/decrease at different times for treated
and endogenous CS26. When significant overall differences
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were found, the Student–Newman–Keuls test was applied
to identify significantly different means.
The above statistical comparisons of the significant phar-
macokinetic parameters obtained for test vs reference
treatment were made using KINETICA™.
ETHICS AND LEGAL CONSIDERATIONS
The study was performed in accordance with the relevant
guidelines of the Declaration of Helsinki, 1964, as amended
in Tokyo, 1975, Venice, 1983, Hong Kong, 1989, and
Somerset West, 1996.
Approval of the study protocol by the relevant local
(Canton Ticino) Research Ethics Committee was obtained
before the start of each study period. Federal Authorities
were informed about the study.
The present Clinical Trial was carried out according to
the general principles of ‘ICH Topic E6, CPMP/ICH/135/95’,
July 1996 including post Step 4 errata, status September
1997.
Results
The 20 subjects enrolled in the study were the same as
in the previous clinical trial26: age (years) 25.2±2.1, weight
(kg) 71.1±5.6, height (cm) 178.1±4.7.
Also for ichthyic origin CS the treatment was well toler-
ated and did not cause relevant changes in vital signs or
ECG.
The basal CS concentrations, endogenous CS, were
calculated in the previous published study26, and they
varied during the day from a minimum average value of
1.53 µg/ml after 10 h (about 6 p.m.) to a maximum average
amount of 3.37 µg/ml after 24 h (about 8 a.m.).
CHARACTERIZATION OF THE STRUCTURE AND PROPERTIES OF
ICHTHYIC CS
Table I summarized the disaccharide composition of
ichthyic CS and its main characteristics, such as the charge
density, 4-sulfated/6-sulfated ratio, and the molecular
mass. Ichthyic CS is composed of a great amount of
disulfated disaccharides (Fig. 1), in particular disulfated in
position 2 of the uronic acid and 6 on N-acetyl-
galactosamine, with a great charge density and a low
percentage of sulfate esterified in position 4 on N-acetyl-
galactosamine16,34–36. Furthermore, ichthyic CS has a
great Mw, approximately ranging from 40.000 to 50.000,
with a low dispersity (Table I and Fig. 2) as determined by
HPSEC29.
QUALITATIVE AND QUANTITATIVE DETERMINATION OF CS
Agarose-gel electrophoresis permits qualitative and
quantitative determination of CS after extraction from
plasma (reviewed in reference 26 for method validation).
CS was qualitatively evaluated by its migration time vs
standard. For example, Fig. 3 illustrates agarose-gel elec-
trophoresis of CS extracted and purified from 1 ml plasma
of subject 4 at different times (from 0 to 48 h) after oral
administration of 4 g of ichthyic CS.
Agarose-gel electrophoresis does not permit the differen-
tiation of CS possessing different structure and character-
istics and, as a consequence, the determination of the
polysaccharide disaccharide pattern is necessary.
ORAL ADMINISTRATION OF ICHTHYIC CS
After administration of ichthyic CS, plasma levels in-
creased in almost all subjects (Fig. 4). Subjects 3 and 14
did not show an increase in CS plasma levels, whilst
subject 7 showed poor absorption. Subject 11 showed a
peak of maximum CS concentration at 4 h, subjects 2, 13,
16, and 18 at 6 h, subjects 1, 8, 10, 12, 17, and 19 at 8 h,
subjects 4, 5, 6, and 15 at 12 h, subjects 9 and 20 at 16 h.
The increase in CS plasma levels was significant from 4 to
16 h after oral administration. In particular, from 6 to 12 h
after drug administration, an increase ranging from 112.50
to 126.06% was reached with respect to baseline (Fig. 4).
The maximum measured plasma concentration was
4.87±2.05 µg/ml with a tmax of 8.7±4.5 h (Table II). After
48 h of drug administration CS plasma levels were detect-
able in all the subjects and averaged 2.13±1.33 µg/ml.
Under basal conditions the AUC0–24 averaged
49.2±16.5 µg×h/ml26. In order to factor out the contribution
of basal CS in the calculation of AUC, the AUC0–24 was
calculated and it averaged 85.0±37.7 µg×h/ml for ichthyic
CS (Table II). The AUC0–48 was 141.4±67.9 µg×h/ml after
administration of CS. In order to further remove the influ-
ence of endogenous CS levels in the calculation of AUC,
the area under the minimum concentration vs time curve up
to 24 h sampling time was calculated for each subject and
subtracted from the AUC0–24. The AUC(0–24) min averaged
56.8±31.1 µg×h/ml after administration of ichthyic CS.
DISACCHARIDE COMPOSITION OF PLASMA ICHTHYIC CS AFTER ITS
ORAL ADMINISTRATION
According to previous studies26,30 the disaccharide com-
position of plasma CS (endogenous) at predose was
Table I
Percentage of unsaturated disaccharides as weight percent (for
structure of disaccharides see the scheme), charge density calcu-
lated as sulfate to carboxyl ratio, and the 4-sulfated/6-sulfated ratio
(4s/6s) of ichthyic CS
R2 R4 R6 CS ichthyic
∆Di-0s H H H 1.7
∆Di-6s H H SO3− 50.0
∆Di-4s H SO3− H 31.1
∆Di-2,6dis SO3− H SO3− 15.8
∆Di-4,6dis H SO3− SO3− 1.0
∆Di-2,4dis SO3− SO3− H 0.4






The number average molecular weight (MWn), the weight
average molecular weight (MWw), and the polydispersity are
reported (see Fig. 2 for HPSEC). The percentage of each un-
saturated disaccharide and of the molecular mass values of the
polysaccharide are averages of five different analyses.
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Fig. 1. SAX-HPLC chromatogram of unsaturated disaccharides of ichthyic and bovine CS. Non-sulfated (0s), 6-sulfated (6s), 4-sulfated (4s),
2,6-disulfated (2,6dis), 4,6-disulfated (4,6dis), 2,4-disulfated (2,4dis), and 2,4,6-trisulfated (tris) disaccharides. For structure see Fig. 1 and
abbreviations.
Fig. 2. HPSEC of ichthyic CS.
Fig. 3. Agarose-gel electrophoresis of endogenous CS (predose, 0) and polysaccharide extracted and purified from subject 4 plasma after
administration of ichthyic CS at various times. (a) 1 µg CS. (b) 3 µg CS. (c) 5 µg CS. 0, Predose; 0.5, 0.5 h; 1, 1 h; 2, 2 h; 4, 4 h; 6, 6 h;
8, 8 h; 12, 12 h; 16, 16 h; 24, 24 h; and 48, 48 h.
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60.40±8.94% of non-sulfated disaccharide and 39.60±
8.94% of 4-sulfated disaccharide (with a sulfate to di-
saccharide ratio of about 0.40) (Fig. 5).
CS of ichthyic origin has a high percentage of monosul-
fated disaccharides in positions 4 (31.1±5.0%) and 6
(50±5.0%) of galactosamine, about 2.0±2.0% of non-
sulfated disaccharide, and about 17% of disulfated disac-
charides mainly composed of disaccharide 2,6-disulfated
(about 16%, Fig. 1), with a sulfate to disaccharide ratio of
about 1.15 (Table I). After the administration of ichthyic
CS a decrease in the relative amount of non-sulfated
disaccharide was measured, reaching the minimum rela-
tive percentage of 30.86±20.79% at 8 h (Fig. 6). At the
same time 4-sulfated disaccharide increased to a maxi-
mum of 51.91±25.91% at 6 h and 6-sulfated and di-sulfated
disaccharides appeared in the blood CS, reaching maxi-
mum concentrations of 15.24±16.60% at 8 h and
2.93±4.82% at 12 h, respectively (Fig. 6). Concomitantly,
the mean charge density rose from 0.40±0.14 at predose to
a maximum of 0.72±0.22 and 0.72±0.21 measured 8 and
12 h after ichthyic CS administration (Fig. 7). After 48 h of
drug administration the composition in disaccharides al-
most returned to basal: ∆Di-0s was 62.07±17.37%, ∆Di-6s
was 2.16±6.59%, and ∆Di-4s was 35.77±16.22%. The
charge density was 0.38±0.17.
Discussion
The oral absorption and bioavailability of ichthyic
origin CS (from shark cartilage) was assessed after oral
administration to 20 healthy male volunteers using the
same methodological approach for studying oral adsorption
of CS from bovine26. Polysaccharide absorbed by oral
route was characterized and quantified by agarose-gel
electrophoretic technique, and densitometric scanning. In
addition, the percentage of constituent disaccharides and
Fig. 4. Mean (n6) plasma concentration of endogenous CS
(µg/ml plasma)26 and mean (n20) plasma concentration of CS
(µg/ml plasma) determined by validated agarose-gel electro-
phoresis and densitometric scanning at different times after admin-
istration of 4 g ichthyic CS. Endogenous CS levels were assessed
in a previous study26 and quantitatively determined by agarose-gel
electrophoresis and densitometric scanning according to the
analytical procedure illustrated above. The day time of blood
samples started at 8 a.m. of day 1 (0 h in the Figure).
Table II
Mean CS plasma pharmacokinetic parameters after administration of 4 g ichthyic CS
Cmax (µg/ml) tmax (h) AUC0–48 (µg×h/ml) AUC0–24 (µg×h/ml)
Mean 4.87 8.7 141.4 85.0
SD 2.05 4.5 67.9 37.7
CV% 42.2 51.3 48.0 44.4
Min 1.5 0.0 34.8 25.2
Max 9.7 16.0 294.2 176.6
n 20 20 20 20
Fig. 5. SAX-HPLC chromatogram of disaccharides of endogenous
CS (predose, subject 1) and after 6 h of oral administration of
ichthyic CS (subject 18). 0s, non-sulfated disaccharide; 6s,
6-sulfated disaccharide; 4s, 4-sulfated disaccharide; and 2,6dis,
2,6-disulfated disaccharide.
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charge density were measured. The combination of
agarose-gel electrophoresis with the determination of un-
saturated disaccharides of CS by HPLC permits us to
obtain quantitative and qualitative information (the pattern
of variously sulfated disaccharides and charge density) on
the modifications of plasma CS after oral administration of
exogenous CS.
The absorption of exogenous ichthyic CS strongly
changed the composition of plasma CS as was evident
by determining unsaturated disaccharides. After drug
administration a decrease of non-sulfated disaccharide and
a concomitant increase of 4-sulfated disaccharide, and
appearance of 6-sulfated disaccharide and disulfated disac-
charides, mainly 2,6-disulfated, was evident. These struc-
tural modifications of plasma CS were evident in particular
from 4 to 16 h after ichthyic CS administration concomitantly
with the increase of polysaccharide plasmatic levels. The
mean sulfate to disaccharide ratio also increased after CS
administration, confirming the presence in human blood of a
more sulfated CS species than endogenous. Furthermore,
CS reaches the blood with a molecular mass greater than
approximately 2000 as determined by agarose-gel electro-
phoresis and still possessing a low but significative amount
of disulfated polysaccharide sequences.
Previous studies have demonstrated that after oral ab-
sorption the mean plasma curve of exogenous CS peaks
after 3.237, 4.038, or 5.0 h39. In the previous trial26, bovine
CS is quickly absorbed with a tmax of 2.4 h, while ichthyic
CS is absorbed with a tmax of 8.7 h. On the contrary, the
Fig. 6. The relative percentage of unsaturated disaccharides in CS determined by HPLC in 20 healthy human volunteers at different times
after administration of 4 g ichthyic CS.
Fig. 7. Charge density (sulfate to disaccharide ratio) of CS deter-
mined in 20 healthy human volunteers at different times after
administration of 4 g ichthyic CS.
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extent of absorption was quite similar. These results give
evidence that structure and properties of polysaccharides
strongly influence their absorption and bioavailability by
oral route. This could be of interest to better design a more
effective therapy. In fact, a possible explanation for the
difference in the absorption profile of different formulations
can be found in the different molecular weights and charge
densities of the two parental molecules. CS of ichthyic
origin has a higher molecular mass than CS obtained from
bovine tissues, thus absorption is likely to be slower. The
rate of metabolic elimination is also likely to be reduced
with high molecular mass molecules. This can account for
the slow absorption, the low peak, and the prolonged
presence of CS in the bloodstream when administered as
ichthyic formulation. This was also experimentally con-
firmed by studying the oral absorption of partially depolym-
erized shark CS in men38 by finding a tmax of 4.0 h.
Moreover the presence of disulfated disaccharides in ich-
thyic CS increases its charge density. This can account for
a stronger bond with plasma proteins, cells, and the en-
dothelial wall from which the molecule would be slowly
released into the bloodstream. In fact, glycosaminoglycans
have been found to interact with several proteins in plasma,
such as protease inhibitors, coagulation factors, lipo-
proteins and complement proteins, as well as cells and
vascular endothelium40,41.
This research strengthens the previous studies in man
and experimental animals26,37–39,42–47 by confirming that
molecules possessing high molecular mass and charge
density can be absorbed orally. Moreover, the absorption
and bioavailability of CS is strongly influenced by its struc-
ture and characteristics, such as molecular mass, charge
density, and cluster of disulfated disaccharides.
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